Structural binding site comparisons reveal Crizotinib as a novel LRRK2 inhibitor. Comput. Struct. Biotechnol. J., (19):3674--3681, Elsevier BV, June 2021. [PUMA: Binding Protein-ligand screening repositioning; site; interactions; Crizotinib; Structure-based LRRK2; Drug]